How KCNH2 (long QT type 2) gene changes affect brain cell activity
Probing mechanisms of long QT type 2-associated neuronal dysfunction using gene-edited stem cell-derived neurons
['FUNDING_R21'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-11239014
Using gene-edited and patient-derived stem cells, researchers will look at how KCNH2 changes linked to long QT type 2 change the way brain cells fire, which may explain higher seizure and sudden-death risk in affected people.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-11239014 on ClinicalTrials.gov |
What this research studies
This project uses human stem cells that are either patient-derived or edited with CRISPR to carry KCNH2 changes seen in long QT type 2. Those stem cells are turned into neurons in the lab so scientists can measure how the hERG1 potassium channel controls neuron activity. The team will compare normal and mutant neurons to find molecular and electrical differences that could make neurons more excitable. Findings aim to link cardiac gene variants to epilepsy risk and sudden unexplained death in epilepsy (SUDEP).
Who could benefit from this research
Good fit: People with diagnosed long QT syndrome type 2 (KCNH2 variants), especially those with a history of seizures or a family history of SUDEP, would be the most relevant candidates to provide samples or be involved in related future studies.
Not a fit: People without KCNH2-related LQTS or whose arrhythmias and seizures have unrelated causes are unlikely to benefit directly from these lab-based findings in the short term.
Why it matters
Potential benefit: If successful, this work could explain why people with LQTS2 have higher seizure and SUDEP risk and point to targets for treatments or monitoring strategies.
How similar studies have performed: Lab studies using gene-edited and patient-derived stem cells have successfully revealed disease mechanisms for other genetic conditions, but applying this approach to KCNH2's effects on neurons and SUDEP risk is relatively new.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JONES, DAVID K. — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: JONES, DAVID K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cardiac Diseases, Cardiac Disorders